PhRMA Medicines in Development Report
We are thrilled to announce that we have released a Medicines in Development report working in collaboration with the Pharmaceutical Research and Manufacturers of America (PhRMA).
The report cites 39 medicines in development for lupus and highlights the story of Stacey Kozel, who has been able to accomplish amazing feats despite having lupus.
These medicines in development include:
- 76 for autoimmune types of arthritis;
- 58 for inflammatory bowel disease;
- 39 for lupus;
- 34 for type 1 diabetes; and
- 32 for multiple sclerosis.
Lupus, which affects an estimated 1.5 million Americans, is just one of the numerous autoimmune diseases with few treatment options. However, new therapies for diseases like lupus move science forward and take steps toward helping patients and their families manage diseases that have a significant effect on their lives.
This report illustrates our commitment to working with all stakeholders to find new treatments that will improve the overall health and wellbeing of people with lupus.
PhRMA’s Research and Hope Awards Ceremony highlighted the new report and increased awareness for the industry’s commitment to autoimmune diseases, lupus in particular.
PhRMA also recognized Dr. Joan Merrill for outstanding Private / Nonprofit Research at the 2016 Research & Hope Awards Annual Dinner. Dr. Merrill has been involved in the design, implementation and execution of clinical trials of immune modulating treatments for more than 20 years. The Research & Hope Awards illustrate how biopharma researchers and others in the innovation ecosystem work together to not only bring new medical advances to patients, but thwart deadly diseases through increased awareness, public health efforts and increased collaboration. This award – and Dr. Merrill’s leadership and research contributions – further raise the profile of lupus among biopharma industry leaders who can support our efforts to deliver treatments and cures in the future.
Check out PhRMA’s release on the Awards here.
You can read PhRMA’s summary blog post on the Medicines in Development report here.
You can access the full report here.